Warner Chilcott Femtrace (Correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Aug. 20 approval of Warner Chilcott Femtrace (estradiol) tablets for the relief of vasomotor symptoms of menopause came on the product's user fee date
You may also be interested in...
Femtrace Launch Planned For Early 2005
Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.